

Glycosylation regulates turnover of cyclooxygenase-2

Mary B. Sevigny^a, Chai-Fei Li^b, Monika Alas^{a,b}, Millie Hughes-Fulford^{b,c,*}

^a Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, USA

^b Laboratory of Cell Growth, Northern California Institute for Research and Education, Veterans Affairs Medical Center, San Francisco, CA 94121, USA

^c University of California, San Francisco, CA 94121, USA

Received 16 July 2006; revised 15 October 2006; accepted 31 October 2006

Available online 9 November 2006

Edited by Judit Ovádi

Abstract Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in the prostanoid biosynthesis pathway, converting arachidonic acid into prostaglandin H₂. COX-2 exists as 72 and 74 kDa glycoforms, the latter resulting from an additional oligosaccharide chain at residue Asn⁵⁸⁰. In this study, Asn⁵⁸⁰ was mutated to determine the biological significance of this variable glycosylation. COS-1 cells transfected with the mutant gene were unable to express the 74 kDa glycoform and were found to accumulate more COX-2 protein and have five times greater COX-2 activity than cells expressing both glycoforms. Thus, COX-2 turnover appears to depend upon glycosylation of the 72 kDa glycoform.

Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.

Keywords: Cyclooxygenase-2; Post-translational regulation; Enzyme turnover; Glycosylation; Glycoforms; Site-directed mutagenesis

1. Introduction

Prostanoids, which consist of prostaglandins and thromboxanes, represent a family of lipid-soluble, bioactive compounds which have been associated with a multitude of physiological processes and pathophysiological conditions that include: platelet aggregation, bone metabolism, ovulation, inflammation, ischemia, and various cancers (reviewed in [1]). The rate-limiting step in the prostanoid synthesis pathway is catalyzed by the integral membrane protein cyclooxygenase (COX), also known as prostaglandin H₂ (PGH₂) synthase [2,3], which is localized to the endoplasmic reticulum (ER) and nuclear envelope [4]. COX is bifunctional, converting arachidonic acid (AA), an omega-6 fatty acid, to the precursor

prostaglandin G₂ (PGG₂) and subsequently converting PGG₂ to the precursor PGH₂ via cyclooxygenase and peroxidase activities, respectively. Three isoforms of COX have been found – the constitutively expressed COX-1 [5–7]; COX-2, which can be inducible or constitutive, depending on the tissue [1,8–10]; and the constitutively expressed COX-3, which is believed to be a splice variant of COX-1 [11]. Although COX-1 is considered the housekeeping enzyme expressed in nearly all tissues, COX-2 is generally perceived to be involved in pathological conditions, such as inflammation and cancer [1,12,13]. In particular, we have found that the presence of AA in human prostate cancer cells up-regulates COX-2 mRNA and protein expression [14,15] – specifically, the 72 kDa glycoform [16]. However, COX-2 is also involved with normal physiological processes such as neurotransmission and synaptic activity [17,18], maintaining normal renal functions [19], providing vascular protection [20], regulating cerebral blood flow [21], and facilitating pregnancy [22].

The COX-2 sequence contains five potential *N*-glycosylation sites, three of which are always glycosylated, one (Asn⁵⁸⁰ in human and mouse) that is glycosylated ≤50% of the time, and one that is never glycosylated [23]. The carbohydrate moieties at each site are believed to be high-mannose chains [24,25]. The variability of glycosylation at Asn⁵⁸⁰ leads to the production of two distinct glycoforms of 72 and 74 kDa. Previous studies have examined this variable glycosylation at the Asn⁵⁸⁰ site, but none were able to determine the purpose or biological significance of the two COX-2 glycoforms [23,25].

In this study, we strove to determine the purpose of glycosylation at Asn⁵⁸⁰ – specifically, if and how this additional glycosylation affects COX-2 activity. We found that glycosylation at Asn⁵⁸⁰ does indeed affect total COX-2 activity by controlling the enzyme's turnover.

2. Materials and methods

2.1. Materials

The human COX-2 cDNA in plasmid pcDNA3 was generously provided by Dr. Timothy Hla from the University of Connecticut, USA. The COS-1 cell line was obtained from the UCSF Cell Culture Facility (San Francisco, CA, USA). QIAprep Spin Miniprep kit, HiSpeed Plasmid Maxi kit, and the primers used for site-directed mutagenesis (5'-TCATTAACAGTCACCATCCAGGCAAGTCTTCCCCTC-3' and 5'-GAGCGGGAAGAAGACTTGCCTGGATGGTGACTGTTT-TAATGA-3') were purchased from QIAGEN (Valencia, CA, USA). The *Pfu*Ultra HF DNA polymerase was purchased from Stratagene (La Jolla, CA, USA). The transfection reagent FuGENE 6 was purchased from Roche Applied Science (Indianapolis, IN, USA). One Shot TOP10 Competent *Escherichia coli* cells, pre-made 4–12% Bis-

*Corresponding author. Address: Laboratory of Cell Growth, Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA. Fax: +1 415 750 6667.

E-mail addresses: millie.hughes-fulford@med.va.gov, milliehf@aol.com (M. Hughes-Fulford).

Abbreviations: COX, cyclooxygenase; AA, arachidonic acid; PGG₂, prostaglandin G₂; PGH₂, prostaglandin H₂; kDa, kilodalton; DMEM, Dulbecco's Modified Eagle's Medium; FBS, fetal bovine serum; PBS, phosphate buffered saline; SDS, sodium dodecyl sulfate; ELISA, enzyme-linked immunosorbent assay; OA, octanoic acid; PGE₂, prostaglandin E₂; PI3K, phosphatidylinositol 3-kinase; NSAIDs, non-steroidal anti-inflammatory drugs; ER, endoplasmic reticulum

Tris NuPAGE gels, and the NuPAGE system were obtained from Invitrogen (Carlsbad, CA, USA). The anti-human COX-2 polyclonal antibody, the prostaglandin E₂ (PGE₂) EIA kit – Monoclonal and peroxide-free AA were purchased from Cayman Chemical (Ann Arbor, MI, USA). Octanoic acid was purchased from Sigma.

2.2. Site-directed mutagenesis

DNA primers were designed to convert the Asn residue at site 580 in the human COX-2 sequence to a Gln residue. The mutagenesis reaction contained pcDNA3-COX-2, sense and antisense DNA primers, dNTP mix, and *Pfu* Ultra HF DNA polymerase. The reaction was incubated at 95 °C for 30 s. This was followed by 16 cycles of: 95 °C for 30 s, 55 °C for 1 min, and 68 °C for 7 min, 30 s. The restriction enzyme *Dpn*I was then added to the reaction to cleave up the original plasmid, leaving intact only plasmids containing the mutant COX-2 gene.

2.3. Transfection of COS-1 cells

One Shot TOP10 Competent *E. coli* cells were used to produce large quantities of plasmid containing either the wild-type or mutant COX-2 gene. Plasmids were isolated and purified using the HiSpeed Plasmid Maxi kit according to the manufacturer's instructions. COS-1 cells were grown on 6-well plates in Dulbecco's Modified Eagle's Medium (DMEM), 1% fetal bovine serum (FBS) media at 37 °C. FuGENE 6 reagent was used to transiently transfect cells with either the wild-type or mutant COX-2 gene according to the manufacturer's instructions. Cells were incubated at 37 °C for 4–5 h in the presence of the FuGENE 6/COX-2 DNA complex. Media was replaced with DMEM, 10% FBS, 4 mM L-glutamine, and antibiotics, and the cells continued their incubation.

2.4. Western blot analyses

Transfected and non-transfected COS-1 cells growing on 6-well plates were washed with ice-cold phosphate buffered saline and then lysed. The whole cell lysates were sonicated briefly and subjected to centrifugation at 14,000 × *g* for 5 min to remove cytoskeletal structures. Protein concentrations were determined, and cell lysate samples underwent gel electrophoresis using either 4–12% Bis-Tris NuPAGE gels or 16 cm, 7% sodium dodecyl sulfate (SDS)-polyacrylamide gels. After electrophoresis, proteins were transferred to nitrocellulose and immunostained for COX-2 protein using anti-human COX-2 polyclonal antibody. The membrane was also immunostained for the housekeeping gene β-actin. Bound antibody was detected using chemiluminescence and film. Densitometry analyses were then carried out using the software UNSCAN-IT by Silk Scientific.

2.5. ELISA for measuring PGE₂ levels

Transfected and non-transfected COS-1 cells growing on 6-well plates were treated with 5 μg/ml of either AA or octanoic acid (OA) for 2 h at 37 °C, as previously described [16]. Media samples were then collected and analyzed for the presence of the downstream product PGE₂ using a PGE₂ EIA kit – Monoclonal. Dilutions of the media samples were prepared in a 96-well plate and were treated and analyzed according to the manufacturer's instructions.

2.6. Statistical analysis

Using Instat 3 software, densitometry data were subjected to One-way Analysis of variance (ANOVA). Enzyme-linked immunosorbent assay (ELISA) results were also subjected to ANOVA followed by the Student–Newman–Keuls Multiple Comparisons Test.

3. Results and discussion

3.1. Mutagenesis of glycosylation site Asn⁵⁸⁰ affects glycoform expression

By replacing asparagine (Asn) with glutamine (Gln) at residue 580 of the human COX-2 gene, we effectively eliminated glycosylation at that site (Fig. 1A). As a result, COS-1 cells transfected with the mutant gene were able to express the 72 but not the 74 kDa glycoform found in cells expressing the wild-type gene. The mutation also resulted in the expression




Fig. 1. COX-2 glycoforms expressed from wild-type and mutant COX-2 genes. (A) Whole cell lysates were analyzed via Western blotting after transient transfection of COS-1 cells with either the wild-type or Asn⁵⁸⁰-mutant COX-2 gene. Each lane was loaded with 15 μg of protein. Blot shown represents a sample size of 10 (*n* = 10). Graph depicts densitometry values of COX-2 bands normalized to β-actin levels. ****P* < 0.0001 compared to WT 72 kDa (Student–Newman–Keuls Multiple Comparisons Test); *n* = 3. (B) Whole cell lysates were analyzed 3, 4, and 5 days after transient transfection with the wild-type or mutant COX-2 gene. Each lane was loaded with 15 μg of protein. Blot shown is representative of duplicate samples (*n* = 2). Graphs depict densitometry values of COX-2 bands normalized to β-actin levels. ANOVA *P* values: *P* = 0.0116 for WT 74 kDa; *P* = 0.0030 for WT 72 kDa; *P* = 0.0049 for MUT 72 kDa; and *P* = 0.0005 for MUT 70 kDa; *n* = 3 for 3-day data; *n* = 2 for 4- and 5-day data. C, non-transfected control cells; WT, cells transfected with the wild-type COX-2 gene; MUT, cells transfected with the mutant gene.

of a “new” 70 kDa glycoform, but the mechanism behind its formation is as yet unknown. Fig. 1A shows a significantly large accumulation of both the 70 and the 72 kDa proteins. In short, removal of the glycosylation site appeared to increase total COX-2 protein levels. To confirm this, a timecourse experiment was conducted in which expression patterns of the glycoforms were analyzed 3, 4, and 5 days after transient transfection with either the wild-type or mutant COX-2 gene (Fig. 1B). The concentrations of the two glycoforms expressed from the mutant gene continued to be greater than those expressed from the wild-type gene, even as total COX-2 expression started to wane by Day 5. This verified that removal of the Asn⁵⁸⁰ glycosylation site slowed down the turnover of the COX-2 protein.

3.2. Effect of glycosylation on total COX-2 activity

To determine if the accumulation of COX-2 in cells expressing the mutant gene also resulted in an increase in total COX-2 activity, levels of the downstream end-product PGE₂ were measured (Fig. 2). Cells carrying either the wild-type (WT) or mutant (MUT) COX-2 gene were treated with the COX-2 substrate AA for 2 h. PGE₂, released by cells into the media, was measured using an ELISA. As Fig. 2 shows, AA-treated cells expressing the 70/72 kDa glycoforms had the greatest PGE₂ levels – five times greater than the levels found in AA-treated cells expressing the 72/74 kDa glycoforms. PGE₂ was also measured in untreated cells and in cells treated with the non-substrate fatty acid, OA. As expected, PGE₂ levels were extremely low in the untreated and OA-treated cell groups, and there were no significant differences between the two groups.

3.3. Effect of AA on COX-2 glycoform expression

Although the presence of AA can lead to an increase in COX-2 by indirectly up-regulating its transcription [15,26], the mutant and wild-type COX-2 gene constructs used in this study were under the control of the pcDNA3 plasmid’s CMV promoter rather than their native COX-2 promoter. Thus, the increased COX-2 activity in AA-treated cells (shown in Fig. 2) was not due to an increase in COX-2 production.




Fig. 2. Comparing activities of COX-2 glycoforms in the presence of AA or OA. Three days after transient transfection of COS-1 cells with either the wild-type (72/74 kDa) or mutant (70/72 kDa) COX-2 gene, cells were treated with 5 μ g/ml of arachidonic acid (AA) or octanoic acid (OA) for 2 h at 37 °C. Media was then analyzed for PGE₂ using an ELISA. Neg. Control, non-transfected cells. Data are represented as average \pm S.E.M. * P < 0.05 compared to other two “AA-treated” groups; ** P < 0.001 compared to other two “72/74 kDa” groups; n = 3.




Fig. 3. Effect of arachidonic and octanoic acid on COX-2 protein expression. Three days after transient transfection of COS-1 cells with either the wild-type (WT) or mutant (MUT) COX-2 gene, cells were treated with 5 μ g/ml of arachidonic acid (AA) or octanoic acid (OA) for 2 h at 37 °C. Whole cell lysates were then analyzed via Western blotting, each lane loaded with 10 μ g of protein. Blot shown is representative of triplicate samples (n = 3). Graph depicts densitometry values of COX-2 bands normalized to β -actin levels. No statistically significant differences were found between non-treated (1), AA-treated (2), or OA-treated (3) samples for either the WT or MUT groups; n = 3.

However, to confirm that AA treatment had no effect on COX-2 protein synthesis, a Western blot was carried out on the same treatment groups described in Fig. 2. Fig. 3 shows that AA-treated cells produced the same level of COX-2 protein as control cells (i.e. untreated and OA-treated cells).

3.4. Conclusion

A few past studies have examined the glycosylation of COX-2, but none succeeded in determining the significance or purpose of the two COX-2 glycoforms. Though researchers found glycosylation of COX-2 at Asn⁵³, Asn¹³⁰, and Asn³⁹⁶ necessary for proper folding of COX-2 into an active, 72 kDa enzyme [23], no such function was found for the glycosylation site Asn⁵⁸⁰. Ours is the first study to describe a biologically significant role for the glycosylation of Asn⁵⁸⁰ in the COX-2 protein. Additionally, our study introduces a new regulatory mechanism for COX-2 expression. Regulation of COX-2 at the levels of transcription (reviewed in [27]) and post-transcription (i.e. mRNA stability) [28,29] has already been well-established. In fact, we previously demonstrated that AA regulates COX-2 transcription via a feed-forward mechanism in prostate cancer [15,26], most likely mediated by the EP4 prostaglandin receptor [30] and by activation of phosphatidylinositol 3-kinase (PI3K) [16]. However, regulation after protein synthesis appeared to be limited to the addition of exogenous COX-2 enzyme inhibitors (e.g. non-steroidal anti-inflammatory drugs (NSAIDs)) [1]. As our study indicates, removal of glycosylation site Asn⁵⁸⁰ in the human COX-2 protein leads to an increase in total COX-2 activity (as reflected by a five-fold increase in PGE₂) and an accumulation of both the 72 kDa and 70 kDa COX-2 glycoforms. Although the structure and activity level of the 70 kDa protein have yet to be determined, it is entirely possible that this glycoform contributed significantly

to the overall increase in COX-2 activity found in the Asn⁵⁸⁰-mutant cells. All these data suggest that normal turnover of COX-2 requires the conversion of the 72 kDa protein into the 74 kDa glycoform via glycosylation, indicating that regulation of COX-2 can also occur at the post-translational level. This finding may be particularly important from a therapeutic perspective since increased levels of COX-2 protein have been implicated in various pathological conditions, and glycosylation of COX-2 appears to be involved with controlling those levels.

Acknowledgements: The authors thank Dr. Timothy Hla (University of Connecticut) for the generous gift of the human COX-2 cDNA. These studies were supported by the Veterans Administration Merit Review Award and in part by the VA REAP and NASA Grants NCC-2-1361 and NAG-2-2981 awarded to M. H-F.

References

- [1] Hinz, B. and Brune, K. (2002) Cyclooxygenase-2 – 10 years later. *J. Pharmacol. Exp. Ther.* 300, 367–375.
- [2] Bailey, J.M., Muza, B., Hla, T. and Salata, K. (1985) Restoration of prostacyclin synthase in vascular smooth muscle cells after aspirin treatment: regulation by epidermal growth factor. *J. Lipid Res.* 26, 54–61.
- [3] Whiteley, P.J. and Needleman, P. (1984) Mechanism of enhanced fibroblast arachidonic acid metabolism by mononuclear cell factor. *J. Clin. Invest.* 74, 2249–2253.
- [4] Reiger, M.K., DeWitt, D.L., Schindler, M.S. and Smith, W.L. (1993) Subcellular localization of prostaglandin endoperoxide synthase-2 in murine 3T3 cells. *Arch. Biochem. Biophys.* 301, 439–444.
- [5] DeWitt, D.L. and Smith, W.L. (1988) Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. *Proc. Natl. Acad. Sci. USA* 85, 1412–1416.
- [6] Hla, T., Farrell, M., Kumar, A. and Bailey, J.M. (1986) Isolation of the cDNA for human prostaglandin H synthase. *Prostaglandins* 32, 829–845.
- [7] Merlie, J.P., Fagan, D., Mudd, J. and Needleman, P. (1988) Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). *J. Biol. Chem.* 263, 3550–3553.
- [8] Kujubu, D.A., Fletcher, B.S., Varnum, B.C., Lim, R.W. and Herschman, H.R. (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. *J. Biol. Chem.* 266, 12866–12872.
- [9] Xie, W.L., Chipman, J.G., Robertson, D.L., Erikson, R.L. and Simmons, D.L. (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. *Proc. Natl. Acad. Sci. USA* 88, 2692–2696.
- [10] Smith, W.L. and Langenbach, R. (2001) Why there are two cyclooxygenase isozymes. *J. Clin. Invest.* 107, 1491–1495.
- [11] Chandrasekharan, N.V., Dai, H., Roos, K.L., Evanson, N.K., Tomsik, J., Elton, T.S. and Simmons, D.L. (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc. Natl. Acad. Sci. USA* 99, 13926–13931.
- [12] Bakhle, Y.S. (2001) COX-2 and cancer: a new approach to an old problem. *Br. J. Pharmacol.* 134, 1137–1150.
- [13] Hla, T., Bishop-Bailey, D., Liu, C.H., Schaeffers, H.J. and Trifan, O.C. (1999) Cyclooxygenase-1 and -2 isoenzymes. *Int. J. Biochem. Cell Biol.* 31, 551–557.
- [14] Hughes-Fulford, M., Chen, Y. and Tjandrawinata, R.R. (2001) Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. *Carcinogenesis* 22, 701–707.
- [15] Tjandrawinata, R.R., Dahiya, R. and Hughes-Fulford, M. (1997) Induction of cyclo-oxygenase-2 mRNA by prostaglandin E₂ in human prostatic carcinoma cells. *Br. J. Cancer* 75, 1111–1118.
- [16] Hughes-Fulford, M., Li, C.F., Boonyaratanakornkit, J. and Sayyah, S. (2006) Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. *Cancer Res.* 66, 1427–1433.
- [17] Breder, C.D., Dewitt, D. and Kraig, R.P. (1995) Characterization of inducible cyclooxygenase in rat brain. *J. Comp. Neurol.* 355, 296–315.
- [18] Kaufmann, W.E., Worley, P.F., Pegg, J., Bremer, M. and Isakson, P. (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. *Proc. Natl. Acad. Sci. USA* 93, 2317–2321.
- [19] Traynor, T.R., Smart, A., Briggs, J.P. and Schnermann, J. (1999) Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. *Am. J. Physiol.* 277, F706–F710.
- [20] Topper, J.N., Cai, J., Falb, D. and Gimbrone Jr., M.A. (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. *Proc. Natl. Acad. Sci. USA* 93, 10417–10422.
- [21] Li, D.Y., Hardy, P., Abran, D., Martinez-Bermudez, A.K., Guerguerian, A.M., Bhattacharya, M., Almazan, G., Menezes, R., Peri, K.G., Varma, D.R. and Chemtob, S. (1997) Key role for cyclooxygenase-2 in PGE₂ and PGF₂α receptor regulation and cerebral blood flow of the newborn. *Am. J. Physiol.* 273, R1283–R1290.
- [22] Gibb, W. and Sun, M. (1996) Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. *J. Endocrinol.* 150, 497–503.
- [23] Otto, J.C., DeWitt, D.L. and Smith, W.L. (1993) N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. *J. Biol. Chem.* 268, 18234–18242.
- [24] Nemeth, J.F., Hochgesang Jr., G.P., Marnett, L.J. and Caprioli, R.M. (2001) Characterization of the glycosylation sites in cyclooxygenase-2 using mass spectrometry. *Biochemistry* 40, 3109–3116.
- [25] Percival, M.D., Bastien, L., Griffin, P.R., Kargman, S., Ouellet, M. and O'Neill, G.P. (1997) Investigation of human cyclooxygenase-2 glycosylation heterogeneity and protein expression in insect and mammalian cell expression systems. *Protein Exp. Purif.* 9, 388–398.
- [26] Tjandrawinata, R.R. and Hughes-Fulford, M. (1997) Up-regulation of cyclooxygenase-2 by product-prostaglandin E₂. *Adv. Exp. Med. Biol.* 407, 163–170.
- [27] Hla, T., Ristimaki, A., Appleby, S. and Barriocanal, J.G. (1993) Cyclooxygenase gene expression in inflammation and angiogenesis. *Ann. NY Acad. Sci.* 696, 197–204.
- [28] Dixon, D.A., Kaplan, C.D., McIntyre, T.M., Zimmerman, G.A. and Prescott, S.M. (2000) Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region. *J. Biol. Chem.* 275, 11750–11757.
- [29] Ristimaki, A., Garfinkel, S., Wessendorf, J., Maciag, T. and Hla, T. (1994) Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. *J. Biol. Chem.* 269, 11769–11775.
- [30] Chen, Y. and Hughes-Fulford, M. (2000) Prostaglandin E₂ and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. *Br. J. Cancer* 82, 2000–2006.